We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




RFA Destroys Kidney Cancers and Deters Recurrence

By HospiMedica staff writers
Posted on 20 Feb 2003
A study has shown that radiofrequency ablation (RFA) destroyed all renal cell carcinoma tumors in 34 patients, of whom 32 have had no local recurrence during the follow-up period. More...
The results were reported in the February 2003 issue of Radiology.

Renal cell carcinoma is the most common form of kidney cancer and is most often treated with surgical removal. Researchers at several medical centers have used RFA for patients for whom surgery was not an option. The current study reports on what may be the largest number of such patients treated and the longest follow-up time. RFA delivers heat generated by electrical energy to tumor sites through a thin needle, with placement guided by ultrasound or other imaging technique.

A total of 42 individual tumors were treated in the new study, ranging in size from 1-9 cm. All tumors located on the surface of the kidney were completely destroyed, regardless of size. While larger tumors within the central kidney were more difficult to treat, more than half of those treated were destroyed with additional treatments. Follow-up ranged from three months to three-and-a-half years. Four patients died of unrelated causes, two of whom had no tumor recurrence. The other 30 patients have had no local recurrence. None of the patients with limited kidney function needed to have dialysis.

"I am optimistic that, with further study, RFA will someday become the standard of care for selected kidney tumors,” said W. Scott McDougal, M.D., a co-author and chief of urology at Massachusetts General Hospital (Boston, USA).




Related Links:
Massachusetts General Hospital

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.